CoChat

The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer

Open access

The DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.

Abstract

Colitis-associated cancer (CAC) is a major complication of inflammatory bowel diseases. We show that components of the inflammasome are protective during acute and recurring colitis and CAC in the dextran sulfate sodium (DSS) and azoxymethane + DSS models. Mice lacking the inflammasome adaptor protein PYCARD (ASC) and caspase-1 demonstrate increased disease outcome, morbidity, histopathology, and polyp formation. The increased tumor burden is correlated with attenuated levels of IL-1beta and IL-18 at the tumor site. To decipher the nucleotide-binding domain, leucine-rich-repeat-containing (NLR) component that is involved in colitis and CAC, we assessed Nlrp3 and Nlrc4 deficient mice. Nlrp3(-/-) mice showed an increase in acute and recurring colitis and CAC, although the disease outcome was less severe in Nlrp3(-/-) mice than in Pycard(-/-) or Casp1(-/-) animals. No significant differences were observed in disease progression or outcome in Nlrc4(-/-) mice compared with similarly treated wild-type animals. Bone marrow reconstitution experiments show that Nlrp3 gene expression and function in hematopoietic cells, rather than intestinal epithelial cells or stromal cells, is responsible for protection against increased tumorigenesis. These data suggest that the inflammasome functions as an attenuator of colitis and CAC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1084/jem.20100050

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. NLR inflammasome components attenuate acute ulcerative colitis. (A) Schematic of the acute model of DSS-induced ulcerative colitis. (B) Kaplan-Meier plot of WT, Nlrp3−/−, Pycard−/−, and Casp1−/− mouse survival. (C) Weight loss of WT, Nlrp3−/−, and Pycard−/− mice. (D) Clinical parameters (weight loss, stool consistency, bleeding) of indicated mice. Data shown are representative of at least three independent experiments and depict the mean ± SEM. The symbols # and § indicate P < 0.05 and P < 0.01, respectively, between the mock- and DSS-treated WT; * indicates P < 0.05 between the DSS-treated gene-deficient strains compared with DSS-treated WT. WT mock, n = 4; DSS-treated WT, n = 14; Pycard−/−, n = 4; Nlrp3−/−, n = 6; Casp1−/−, n = 4. Casp1−/− animals were highly sensitive to the acute administration of DSS and were not subjected to additional monitoring described in C and D for humane reasons.
Figure 1. NLR inflammasome components attenuate acute ulcerative colitis. (A) Schematic of the acute model of DSS-induced ulcerative colitis. (B) Kaplan-Meier plot of WT, Nlrp3−/−, Pycard−/−, and Casp1−/− mouse survival. (C) Weight loss of WT, Nlrp3−/−, and Pycard−/− mice. (D) Clinical parameters (weight loss, stool consistency, bleeding) of indicated mice. Data shown are representative of at least three independent experiments and depict the mean ± SEM. The symbols # and § indicate P < 0.05 and P < 0.01, respectively, between the mock- and DSS-treated WT; * indicates P < 0.05 between the DSS-treated gene-deficient strains compared with DSS-treated WT. WT mock, n = 4; DSS-treated WT, n = 14; Pycard−/−, n = 4; Nlrp3−/−, n = 6; Casp1−/−, n = 4. Casp1−/− animals were highly sensitive to the acute administration of DSS and were not subjected to additional monitoring described in C and D for humane reasons.CC BY-NC-SA · PubMed Central
Figure 2. NLR inflammasome components attenuate recurring ulcerative colitis. (A) Schematic of the recurring model of DSS-induced ulcerative colitis. (B–D) Weight loss of Pycard−/−, Nlrp3−/−, and Casp1−/− mice after DSS challenge. (E) Clinical parameters (weight loss, stool consistency, and bleeding) of indicated mice. These data are the averages of each clinical score collected throughout the recurring colitis model. (F) Colon length of indicated mice. (G) Colon histopathology scores reflecting the severity of inflammation, epithelial defects, crypt atrophy, and area affected in hematoxylin and eosin–stained sections through the mid and distal colon. The individual scores are shown in Fig. S2 and summed to generate a HAI. Colon length and histopathology were assessed in the Casp1−/− animals on day 40, whereas these two parameters were assessed on day 57 in the other genotypes tested. Data shown are representative of three independent experiments and depict the mean ± SEM. Error bars have been omitted from the weight loss data for clarity of presentation. The symbols # and § indicate P < 0.05 and P < 0.01, respectively, between the mock- and DSS-treated WT; * indicates P < 0.05 between the DSS-treated gene-deficient strains and WT. WT mock, n = 5; WT, n = 5; Pycard−/−, n = 3; Casp1−/−, n = 4; Nlrp3−/−, n = 3.
Figure 2. NLR inflammasome components attenuate recurring ulcerative colitis. (A) Schematic of the recurring model of DSS-induced ulcerative colitis. (B–D) Weight loss of Pycard−/−, Nlrp3−/−, and Casp1−/− mice after DSS challenge. (E) Clinical parameters (weight loss, stool consistency, and bleeding) of indicated mice. These data are the averages of each clinical score collected throughout the recurring colitis model. (F) Colon length of indicated mice. (G) Colon histopathology scores reflecting the severity of inflammation, epithelial defects, crypt atrophy, and area affected in hematoxylin and eosin–stained sections through the mid and distal colon. The individual scores are shown in Fig. S2 and summed to generate a HAI. Colon length and histopathology were assessed in the Casp1−/− animals on day 40, whereas these two parameters were assessed on day 57 in the other genotypes tested. Data shown are representative of three independent experiments and depict the mean ± SEM. Error bars have been omitted from the weight loss data for clarity of presentation. The symbols # and § indicate P < 0.05 and P < 0.01, respectively, between the mock- and DSS-treated WT; * indicates P < 0.05 between the DSS-treated gene-deficient strains and WT. WT mock, n = 5; WT, n = 5; Pycard−/−, n = 3; Casp1−/−, n = 4; Nlrp3−/−, n = 3.CC BY-NC-SA · PubMed Central
Figure 3. Casp1−/− and Pycard−/− mice are highly susceptible to inflammation-driven colon tumorigenesis. (A) Schematic of the four stage model of inflammation-driven tumor progression using the chemical carcinogen AOM and DSS. (B) Kaplan-Meier plot of WT, Casp1−/−, and Pycard−/− mouse survival. (C and D) Weight loss after AOM+DSS challenge. (E) Clinical parameters associated with increased gastrointestinal disease. (F) Inflammation and tumors revealed by in vivo high resolution endoscopy of during week 6 of the recurring colitis-driven tumor model. Asterisks indicate large tumors throughout the distal colons. (G) Colon histopathology scores reveal the severity of inflammation, epithelial defects, crypt atrophy, dysplasia, hyperplasia, and area affected in hematoxylin and eosin–stained sections through the mid and distal colon shown, as in Fig. S3. These scores were summed together to generate a HAI. Data shown are representative of three independent experiments and depict the mean ± SEM. Error bars have been omitted from the weight loss data for clarity of presentation. The symbol # indicates P < 0.05 between the AOM/mock and AOM/DSS-treated WT; * indicates P < 0.05 between the gene-deficient strains and WT. For the survival study: WT AOM/mock, n = 6; Casp1−/− n = 8; Pycard−/− n = 9; WT n = 9. For all other datasets: WT AOM, n = 3; WT, n = 9; Pycard−/−, n = 6; Casp1−/−, n = 3.
Figure 3. Casp1−/− and Pycard−/− mice are highly susceptible to inflammation-driven colon tumorigenesis. (A) Schematic of the four stage model of inflammation-driven tumor progression using the chemical carcinogen AOM and DSS. (B) Kaplan-Meier plot of WT, Casp1−/−, and Pycard−/− mouse survival. (C and D) Weight loss after AOM+DSS challenge. (E) Clinical parameters associated with increased gastrointestinal disease. (F) Inflammation and tumors revealed by in vivo high resolution endoscopy of during week 6 of the recurring colitis-driven tumor model. Asterisks indicate large tumors throughout the distal colons. (G) Colon histopathology scores reveal the severity of inflammation, epithelial defects, crypt atrophy, dysplasia, hyperplasia, and area affected in hematoxylin and eosin–stained sections through the mid and distal colon shown, as in Fig. S3. These scores were summed together to generate a HAI. Data shown are representative of three independent experiments and depict the mean ± SEM. Error bars have been omitted from the weight loss data for clarity of presentation. The symbol # indicates P < 0.05 between the AOM/mock and AOM/DSS-treated WT; * indicates P < 0.05 between the gene-deficient strains and WT. For the survival study: WT AOM/mock, n = 6; Casp1−/− n = 8; Pycard−/− n = 9; WT n = 9. For all other datasets: WT AOM, n = 3; WT, n = 9; Pycard−/−, n = 6; Casp1−/−, n = 3.CC BY-NC-SA · PubMed Central
Figure 4. Reduced IL-1β and IL-18 production in colons isolated from Pycard and caspase-1 deficient mice. Colons isolated from the indicated AOM+DSS-challenged mice were cultured overnight and IL-1β (A), IL-18 (B), and TNF (C) in the supernatants was measured by ELISA. Data shown are representative of at least three independent experiments and depict the mean ± SEM. The symbol # indicates P < 0.05 between the AOM/mock and AOM/DSS-treated WT; * indicates P < 0.05 between the gene-deficient strains and WT. AOM/mock, n = 3; WT, n = 6; Pycard−/−, n = 3; Casp1−/−, n = 3.
Figure 4. Reduced IL-1β and IL-18 production in colons isolated from Pycard and caspase-1 deficient mice. Colons isolated from the indicated AOM+DSS-challenged mice were cultured overnight and IL-1β (A), IL-18 (B), and TNF (C) in the supernatants was measured by ELISA. Data shown are representative of at least three independent experiments and depict the mean ± SEM. The symbol # indicates P < 0.05 between the AOM/mock and AOM/DSS-treated WT; * indicates P < 0.05 between the gene-deficient strains and WT. AOM/mock, n = 3; WT, n = 6; Pycard−/−, n = 3; Casp1−/−, n = 3.CC BY-NC-SA · PubMed Central
Figure 5. Loss of Nlrp3 results in augmented features of ulcerative colitis in the inflammation-driven tumor model. (A) Schematic of the CAC model using the chemical carcinogen AOM and DSS. (B and C) Weight loss measured throughout the colitis driven tumor progression model in WT, Nlrp3−/−, and Nlrc4−/− mice (difference observed during the final week of study in C is not statistically significant). (D) Clinical scores reflecting weight loss, loose stool consistency, and amounts of blood present in stool and rectum. (E) Colon length. (F) Gross morphology revealing areas of excessive wall thickening and hemorrhage. Data shown are representative of 3 independent experiments and depict the mean ± SEM. Error bars have been omitted from the weight loss data for clarity of presentation. The symbols # and § indicate P < 0.05 and P < 0.01, respectively, between the AOM/mock and AOM/DSS-treated WT; * indicates P < 0.05 between the Nlrp3−/− and WT mice. WT, n = 15; Nlrp3−/−, n = 12; Nlrc4−/−, n = 4; WT AOM/mock, n = 3.
Figure 5. Loss of Nlrp3 results in augmented features of ulcerative colitis in the inflammation-driven tumor model. (A) Schematic of the CAC model using the chemical carcinogen AOM and DSS. (B and C) Weight loss measured throughout the colitis driven tumor progression model in WT, Nlrp3−/−, and Nlrc4−/− mice (difference observed during the final week of study in C is not statistically significant). (D) Clinical scores reflecting weight loss, loose stool consistency, and amounts of blood present in stool and rectum. (E) Colon length. (F) Gross morphology revealing areas of excessive wall thickening and hemorrhage. Data shown are representative of 3 independent experiments and depict the mean ± SEM. Error bars have been omitted from the weight loss data for clarity of presentation. The symbols # and § indicate P < 0.05 and P < 0.01, respectively, between the AOM/mock and AOM/DSS-treated WT; * indicates P < 0.05 between the Nlrp3−/− and WT mice. WT, n = 15; Nlrp3−/−, n = 12; Nlrc4−/−, n = 4; WT AOM/mock, n = 3.CC BY-NC-SA · PubMed Central
Figure 6. NLRP3 mediates gastrointestinal tumorigenesis in the CAC model. (A) Endoscopic analysis of mice during week 6 of the recurring CAC model. (B) Macroscopic polyps were quantified in indicated mice. (C) Size and weight of representative macroscopic polyps from indicated mice. (D) Composite HAI scores. (E–G) Distal colon hyperplasia (E), dysplasia (F), and area involved with disease (G). Data are representative of three independent experiments. The symbol # indicates P < 0.05 between the AOM/mock and AOM/DSS-treated WT; * and ** indicate P < 0.05 and P < 0.01, respectively, between the Nlrp3−/− and WT mice. WT AOM, n = 3; WT, n = 10; Nlrc4−/−, n = 3; Nlrp3−/−, n = 6.
Figure 6. NLRP3 mediates gastrointestinal tumorigenesis in the CAC model. (A) Endoscopic analysis of mice during week 6 of the recurring CAC model. (B) Macroscopic polyps were quantified in indicated mice. (C) Size and weight of representative macroscopic polyps from indicated mice. (D) Composite HAI scores. (E–G) Distal colon hyperplasia (E), dysplasia (F), and area involved with disease (G). Data are representative of three independent experiments. The symbol # indicates P < 0.05 between the AOM/mock and AOM/DSS-treated WT; * and ** indicate P < 0.05 and P < 0.01, respectively, between the Nlrp3−/− and WT mice. WT AOM, n = 3; WT, n = 10; Nlrc4−/−, n = 3; Nlrp3−/−, n = 6.CC BY-NC-SA · PubMed Central
Figure 7. Mice receiving bone marrow from Nlrp3−/− animals develop enhanced gastrointestinal disease. (A) Schematic of the four stage model of inflammation-driven tumor progression using the chemical carcinogen AOM in bone marrow chimeric mice. (B) Weight change of indicated BM chimeras. (C) Composite clinical scores reflecting weight loss, loose stool consistency, and blood in the stool and rectum. (D) Colon length. (E) Composite HAI scores. (F) Quantification of macroscopic polyps. Data depict the mean ± SEM and are representative of three independent experiments. The symbol * indicates P < 0.05 in a comparison of the WT→WT control to the other three groups. WT→Nlrp3−/−, n = 7; Nlrp3−/−→WT, n = 7; WT→WT, n = 3; Nlrp3−/−→Nlrp3−/−, n = 3.
Figure 7. Mice receiving bone marrow from Nlrp3−/− animals develop enhanced gastrointestinal disease. (A) Schematic of the four stage model of inflammation-driven tumor progression using the chemical carcinogen AOM in bone marrow chimeric mice. (B) Weight change of indicated BM chimeras. (C) Composite clinical scores reflecting weight loss, loose stool consistency, and blood in the stool and rectum. (D) Colon length. (E) Composite HAI scores. (F) Quantification of macroscopic polyps. Data depict the mean ± SEM and are representative of three independent experiments. The symbol * indicates P < 0.05 in a comparison of the WT→WT control to the other three groups. WT→Nlrp3−/−, n = 7; Nlrp3−/−→WT, n = 7; WT→WT, n = 3; Nlrp3−/−→Nlrp3−/−, n = 3.CC BY-NC-SA · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 43 references

Cited by

See all 849

Metadata

Authors
Allen, I. C., TeKippe, E. M., Woodford, R.-M. T., Uronis, J. M., Holl, E. K., Rogers, A. B., Herfarth, H. H., Jobin, C., & Ting, J. P.-Y.
Affiliations
  • University of North Carolina at Chapel Hill (US)
  • Lineberger Comprehensive Cancer Center 1 , 2 , 3 , 4 , 5 , 6 , 7
Corresponding author
Ting, Jenny P.-Y.
Venue
Journal of Experimental Medicine
Published
2010-04-12
Volume
207
Issue
5
Pages
1045-1056
ISSN
  • 0022-1007 (ISSN-L)
  • 1540-9538
OpenAlex
W2058590329
Cited by
826
References
44
Citations by year
2026: 28 · 2025: 34 · 2024: 54 · 2023: 54 · 2022: 66 · 2021: 53 · 2020: 43 · 2019: 55 · 2018: 54 · 2017: 61 · 2016: 45 · 2015: 56 · 2014: 51 · 2013: 62 · 2012: 49
FWCI
22.29
Type
journal article
Language
en
Open access
Locations
  • The Journal of Experimental Medicine (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
  • VTechWorks (Virginia Tech) (submittedVersion, cc-by-nc-sa)
Funders
  • National Institutes of Health (2t32ar007416-25)
  • National Cancer Institute (T32CA009156)
  • National Institute of Allergy and Infectious Diseases (F32AI082895, U19AI077437, U19-AI077437-01)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01DK073338, P30‐DK34987, P30DK034987)
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (T32-AR007416)
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (T32HD046369)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
  • Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
  • Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
Keywords
NLRP3 inflammasome, colitis-associated colorectal cancer, inflammatory bowel disease, carcinogenesis, caspase-1, IL-1β, IL-18, NLRP3 knockout mice, NLRC4, hematopoietic cells, bone marrow reconstitution, DSS-induced colitis, azoxymethane, intestinal polyps
MeSH terms
NLR Family, Pyrin Domain-Containing 3 Protein, Animals, Carrier Proteins, Colitis, Colon, Cytoskeletal Proteins, Euthanasia, Humans, Neoplasms, Inflammatory Bowel Diseases, Gene Expression Regulation, Neoplastic, Mice, Knockout, Interleukin-18, Tumor Burden, Apoptosis Regulatory Proteins, Mice, CARD Signaling Adaptor Proteins, Interleukin-1beta

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. https://app.cochat.ai/papers/10.1084/jem.20100050
The paper
Allen, I. C., TeKippe, E. M., Woodford, R.-M. T., Uronis, J. M., Holl, E. K., Rogers, A. B., Herfarth, H. H., Jobin, C., & Ting, J. P.-Y. (2010). The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. Journal of Experimental Medicine. https://doi.org/10.1084/jem.20100050

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.